曲美他嗪联合美托洛尔治疗风湿性心脏病合并慢性心力衰竭的疗效及对心肌功能的影响

Effect of Trimetazidine Combined with Metoprolol on Rheumatic Heart Disease with Chronic Heart Failure and Its Influence on Myocardial Function

目的分析曲美他嗪联合美托洛尔对风湿性心脏病合并慢心力衰竭的治疗价值.方法选取该院2021年1月—2022年6月收治的82例风湿性心脏病合并慢心力衰竭患者为研究对象,随机分为两组.对照组采用常规治疗,试验组在对照组的基础上使用曲美他嗪联合美托洛尔治疗.比较两组患者的治疗总有效率、心肌功能和生活质量.结果试验组治疗总有效率为95.12%,高于对照组的80.49%,差异有统计学意义(P<0.05).治疗前,两组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)比较,组间差异无统计学意义(P>0.05);治疗后,试验组LVEDD和LVESD短于对照组,LVEF高于对照组,组间差异有统计学意义(P<0.05).治疗前,两组6 min步行试验(6MWT)距离和生活质量评估量表(QOL)评分比较,组间差异无统计学意义(P>0.05);治疗后,试验组6MWT距离长于对照组,QOL评分高于对照组,组间差异有统计学意义(P<0.05).结论曲美他嗪联合美托洛尔治疗风湿性心脏病合并慢性心力衰竭的疗效显著,有助于改善患者心肌功能,提高生活质量,值得临床推广.

Objective To analyze the value of trimetazidine combined with metoprolol in the treatment of rheumatic heart disease complicated with chronic heart failure.Methods A total of 82 patients with rheumatic heart disease complicated with chronic heart failure admitted to the hospital from January 2021 to June 2022 were selected as the study objects and randomly divided into two groups.The control group received conventional treatment,and the experimental group received trimetazidine combined with metoprolol on the basis of the control group.The total response rate,myocardial function and quality of life were compared between the two groups.Results The total effective rate of the experimental group was 95.12%,which was higher than 80.49%of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and left ventricular ejection fraction(LVEF)between the two groups(P>0.05);after treatment,LVEDD and LVESD of the experimental group were shorter than those of the control group,and LVEF of the experimental group was higher than that of the control group,with statistical significance differences between the two groups(P<0.05).Before treatment,there were no significant difference between the two groups in 6 min walking test(6MWT)distance and Quality of Life(QOL)scores(P>0.05);after treatment,the 6MWT distance of the experimental group was longer than that of the control group,and the QOL score was higher than that of the control group,the differences between the groups were statistically significant(P<0.05).Conclusion Trimetazidine combined with metoprolol in the treatment of rheumatic heart disease complicated with chronic heart failure has a significant effect,can help to improve the myocardial function of patients,improve the quality of life,worthy of clinical promotion.